clinical trial · NCT05519059
Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer
Adlai Nortye Biopharma Co., Ltd.·phase1·completed·n = 15
Advanced or Metastatic Breast CancerPelareorep
brief summary
This ia a multicenter, Single-Arm, Open-Label Phase I Clinical Study Evaluating the Safety and Tolerability of Pelareorep Combined with Paclitaxel Injection and the Intracorporal Process of Pelareorep in Chinese Patients with Advanced or Metastatic Breast Cancer.
started
Oct 11, 2021
primary completion
Sep 29, 2022
completion
May 30, 2023
last updated
Nov 22, 2023
detailed description
This study will enroll patients with advanced or metastatic breast cancer to assess the safety and tolerability of Pelareorep at 1.5×10\^10, 3.0×10\^10, 4.5×10\^10 (TCID50) combined with paclitaxel to fix the MTD or RP2D.
official title
A Multicenter, Single-Arm, Open-Label Phase I Clinical Study of Pelareorep With Paclitaxel in Advanced or Metastatic Breast Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol